← Back to Screener
Acurx Pharmaceuticals, Inc. Common Stock (ACXP)
Price$1.93
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-65.29%
Price vs S&P 500 (4W)-13.31%
VGM Score39.29
Market Capitalization$8.51M
All Metrics
Book Value / Share (Quarterly)$2.07
P/TBV (Annual)7.28x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.81
Price vs S&P 500 (YTD)-31.42%
EPS (TTM)$-4.46
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-4.46
EPS (Annual)$-5.32
ROI (Annual)-151.21%
Cash / Share (Quarterly)$2.73
ROA (Last FY)-103.60%
EBITD / Share (TTM)$-3.96
ROE (5Y Avg)-604.85%
Cash Flow / Share (Annual)$-2.89
P/B Ratio1.21x
P/B Ratio (Quarterly)1.51x
Net Income / Employee (Annual)$-1,991,600
ROA (TTM)-101.70%
EPS Incl Extra (Annual)$-5.32
Current Ratio (Annual)3.18x
Quick Ratio (Quarterly)3.68x
3-Month Avg Trading Volume2.18M
52-Week Price Return-74.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.30
52-Week High$21.00
EPS Excl Extra (Annual)$-5.32
26-Week Price Return-49.36%
Quick Ratio (Annual)3.14x
13-Week Price Return20.73%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.78x
Enterprise Value$-745,300
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.22
3-Month Return Std Dev284.16%
Net Income / Employee (TTM)$-1,874,600
ROE (Last FY)-151.21%
EPS Basic Excl Extra (Annual)$-5.32
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.46
ROI (TTM)-153.93%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.63
Price vs S&P 500 (52W)-102.59%
Year-to-Date Return-20.48%
5-Day Price Return0.51%
EPS Normalized (Annual)$-5.32
ROA (5Y Avg)-176.68%
Month-to-Date Return-8.33%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-5.40
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-604.85%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.46
P/TBV (Quarterly)13.54x
P/B Ratio (Annual)0.99x
Book Value / Share (Annual)$2.24
Price vs S&P 500 (13W)10.99%
Beta-2.11x
Revenue / Share (TTM)$0.00
ROE (TTM)-153.93%
52-Week Low$1.33
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.62est. -0.65
Q1 26-0.62est. -0.65
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACXPAcurx Pharmaceuticals, Inc. Common Stock | — | — | D | $1.93 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel antibiotics for serious infections caused by priority pathogens identified by the WHO, CDC, and FDA. The company's platform targets Gram-positive bacteria and includes both clinical and preclinical drug candidates.